STOCK TITAN
  1. Home
  2. Sec-filings
  3. GYRE
  4. [Form 4] GYRE THERAPEUTICS, INC. Insider Trading Activity

GYRE (GYRE) COO exercises options, sells 34,976 shares but keeps 700,000

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

GYRE Therapeutics Chief Operating Officer Ye Weiguo reported an exercise-and-sell sequence in company stock. On June 4, 2026 and June 5, 2026, he exercised stock options to acquire a total of 34,976 shares of common stock at an exercise price of $0.75 per share and then sold the same number of shares in open-market transactions.

The 19,575-share sale on June 4 occurred at a weighted average price of $6.13 per share in trades ranging from $6.05 to $6.30, while the 15,401-share sale on June 5 was at a weighted average price of $6.40 per share in trades ranging from $6.15 to $6.60. After these transactions, Weiguo directly holds 700,000 shares of GYRE common stock.

Positive

  • None.

Negative

  • None.
Insider Ye Weiguo
Role Chief Operating Officer
Sold 34,976 shs ($219K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 15,401 $0.00 --
Exercise Common Stock 15,401 $0.75 $12K
Sale Common Stock 15,401 $6.40 $99K
Exercise Stock Option (Right to Buy) 19,575 $0.00 --
Exercise Common Stock 19,575 $0.75 $15K
Sale Common Stock 19,575 $6.13 $120K
Holdings After Transaction: Stock Option (Right to Buy) — 862,419 shares (Direct); Common Stock — 715,401 shares (Direct)
Footnotes (1)
  1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.05 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.15 to $6.60. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. These options are vested in full.
Shares sold 34,976 shares Open-market sales on June 4–5, 2026
Option exercise price $0.75/share Stock options exercised for 34,976 shares
June 4 weighted average sale price $6.13/share 19,575 shares sold on June 4, 2026
June 4 price range $6.05–$6.30 Multiple trades on June 4, 2026
June 5 weighted average sale price $6.40/share 15,401 shares sold on June 5, 2026
June 5 price range $6.15–$6.60 Multiple trades on June 5, 2026
Shares held after transactions 700,000 shares Direct GYRE common stock ownership after June 5, 2026
open-market sale financial
"transaction_action: "open-market sale" describes the S-code trades"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action: "derivative exercise/conversion" for M-code entries"
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" for derivative entries"
weighted average sale price financial
"footnote: "The price reported represents the weighted average sale price per share.""
expiration date financial
"expiration_date: options expiring on 2030-10-31"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transactions did GYRE COO Ye Weiguo report in this Form 4?
Ye Weiguo reported exercising stock options for 34,976 GYRE common shares at $0.75 per share and selling the same 34,976 shares in open-market transactions on June 4–5, 2026, converting an option position into cash while retaining a sizable shareholding.

How many GYRE shares did Ye Weiguo sell and at what prices?
He sold 19,575 GYRE common shares at a weighted average price of $6.13 on June 4 and 15,401 shares at $6.40 on June 5. Footnotes note actual trade prices ranged from $6.05–$6.60 across multiple transactions.

What is Ye Weiguo’s remaining GYRE share ownership after these transactions?
Following the reported option exercises and open-market sales, Ye Weiguo directly holds 700,000 shares of GYRE common stock. This figure reflects his position after selling 34,976 shares that were acquired through exercising stock options at an exercise price of $0.75 per share.

Were the GYRE stock sales by Ye Weiguo part of an option exercise?
Yes. The Form 4 shows code M transactions where options with a $0.75 exercise price were exercised for 34,976 shares, matched by S-code open-market sales of the same number of shares, indicating an exercise-and-sell pattern rather than a standalone share sale.

What details do the Form 4 footnotes provide about GYRE share sale prices?
The footnotes state the reported prices are weighted averages, with June 4 sales executed between $6.05 and $6.30 and June 5 sales between $6.15 and $6.60. Full breakdowns of shares sold at each price are available upon request to relevant parties.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ye Weiguo
(Last)(First)(Middle)
C/O GYRE THERAPEUTICS, INC.
12730 HIGH BLUFF DRIVE, SUITE 250
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/04/2026M19,575A$0.75719,575D
Common Stock06/04/2026S19,575D$6.13(1)700,000D
Common Stock06/05/2026M15,401A$0.75715,401D
Common Stock06/05/2026S15,401D$6.4(2)700,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.7506/04/2026M19,575 (3)10/31/2030Common Stock19,575$0877,820D
Stock Option (Right to Buy)$0.7506/05/2026M15,401 (3)10/31/2030Common Stock15,401$0862,419D
Explanation of Responses:
1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.05 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.15 to $6.60. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3. These options are vested in full.
/s/ Weiguo Ye06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR